Bio-Techne (TECH) Stock Price, News & Analysis

Company Overview

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships. The company’s products support a wide range of end users, including academic and government research institutions, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories. Its global footprint encompasses manufacturing sites, research and development centers, and customer support offices designed to facilitate timely delivery and technical assistance.

Originally founded in 1981 as Techne Corporation, the company grew through both organic innovation and strategic acquisitions. Notable milestones include the acquisitions of R&D Systems in 2006, ProteinSimple in 2014 and Advanced Cell Diagnostics in 2016. In 2014, the company adopted the Bio-Techne name to reflect its expanded portfolio of life science tools and diagnostics solutions. These acquisitions have broadened the company’s capabilities in areas such as in situ hybridization, automated capillary-based Western blotting and bioprocess monitoring.

Bio-Techne is led by President and Chief Executive Officer Charles Kummeth, who has been with the company since 2002 and appointed CEO in 2013. Under his leadership, the company has continued to invest in R&D, expand its product pipeline and extend its geographic reach. A seasoned management team oversees operations, strategic planning and integration of new technologies to drive long-term growth and deliver innovative solutions that accelerate scientific discovery and improve patient outcomes.

Key Stats

• Today's Range: $46.42 to $51.00
• 50-Day Range: $47.26 to $60.58
• 52-Week Range: $45.12 to $72.16
• Volume: 5.15 million shs
• Average Volume: 2.52 million shs
• Market Capitalization: $7.97 billion
• P/E Ratio: 73.78
• Dividend Yield: 0.63%
• Price Target: $66.77
• Consensus Rating: Moderate Buy

Bio-Techne Stock Analysis - MarketRank™

Bio-Techne scored higher than 79% of companies evaluated by MarketBeat, and ranked 147th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Bio-Techne has a consensus price target of $66.77, representing about 31.2% upside from its current price of $50.91.

Amount of Analyst Coverage

Bio-Techne has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.83%

Earnings Growth

Earnings for Bio-Techne are expected to grow by 9.83% in the coming year, from $1.73 to $1.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bio-Techne is 73.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bio-Techne is 73.78, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.45.

Price to Earnings Growth Ratio

Bio-Techne has a PEG Ratio of 3.12. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bio-Techne has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.07% of the float of Bio-Techne has been sold short.

Short Interest Ratio / Days to Cover

Bio-Techne has a short interest ratio ("days to cover") of 7.12.

Change versus previous month

Short interest in Bio-Techne has recently decreased by 0.69%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Bio-Techne has a dividend yield of 0.56%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bio-Techne does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Bio-Techne is 46.38%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.84% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.02

News Sentiment

Bio-Techne has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 27 news articles for Bio-Techne this week, compared to 7 articles on an average week.

Search Interest

16 people have searched for TECH on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

4 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Techne insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.30% of the stock of Bio-Techne is held by insiders.

Percentage Held by Institutions

98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TECH Stock Analysis - Frequently Asked Questions

How have TECH shares performed this year?

Bio-Techne's stock was trading at $58.81 at the beginning of the year. Since then, TECH stock has decreased by 13.4% and is now trading at $50.91.

How were Bio-Techne's earnings last quarter?

Bio-Techne Corp (NASDAQ:TECH) posted its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by $0.02. Bio-Techne's quarterly revenue was down 1.5% on a year-over-year basis.
Read the conference call transcript.

When did Bio-Techne's stock split?

Bio-Techne's stock split on Wednesday, November 30th 2022.The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were payable to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Is Bio-Techne buying back stock?

Bio-Techne's board approved a share repurchase plan on Wednesday, May 7th 2025, which authorizes the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could buy up to 6.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its shares are undervalued.

Does Bio-Techne have any subsidiaries?

Bio-Techne subsidiaries include MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and others.

Who are Bio-Techne's major shareholders?

Bio-Techne's top institutional investors include Sumitomo Mitsui Trust Group Inc. (1.31%), Dimensional Fund Advisors LP (1.26%), Bank of New York Mellon Corp (1.12%) and Stephens Investment Management Group LLC (0.71%). Insiders that own company stock include Roeland Nusse, Kim Kelderman and Amy E Herr.
View institutional ownership trends.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

• Ex-Dividend for 2/27 Dividend: 2/13/2026
• Record date for 2/27 Dividend: 2/16/2026
• Dividend Payable: 2/27/2026
• Last Earnings: 5/06/2026
• Today: 5/07/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Record date for 5/29 Dividend: 5/18/2026
• Ex-Dividend for 5/29 Dividend: 5/18/2026
• Dividend Payable: 5/29/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:TECH
• CIK: 842023
• Web: www.bio-techne.com
• Phone: (612) 379-8854
• Fax: 612-656-4400
• Employees: 3,100
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Bio-Techne: $66.77
• High Price Target: $80.00
• Low Price Target: $49.00
• Potential Upside/Downside: +31.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.69
• Trailing P/E Ratio: 73.78
• Forward P/E Ratio: 29.43
• P/E Growth: 3.12
• Net Income: $73.40 million
• Net Margins: 9.05%
• Pretax Margin: 12.15%
• Return on Equity: 13.57%
• Return on Assets: 10.66%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 4.49
• Quick Ratio: 3.08

Sales & Book Value

• Annual Sales: $1.21 billion
• Price / Sales: 6.58
• Cash Flow: $2.63 per share
• Price / Cash Flow: 19.39
• Book Value: $13.33 per share
• Price / Book: 3.82

Miscellaneous

• Outstanding Shares: 156,453,000
• Free Float: 154,419,000
• Market Cap: $7.97 billion
• Optionable: Optionable
• Beta: 1.41